Saxony promotes biotech
This article was originally published in Clinica
The German state of Saxony is consolidating its position as one of the leading international regions for biotechnology and medical research. Last week saw the opening of the interdisciplinary Max-Bergmann centre for biomaterials in Dresden. Built at a cost of E14 million ($12.4 million), the centre was established by the Dresden Institute for Polymer Research (IPF) and the Technical University of Dresden. The project was financed by the federal ministry for education and research (BMBF), the Saxon ministry for science and art and the European fund for regional development.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.